Commentary: Mapping out Novartis's "pathways" approach to R&D
This article was originally published in Scrip
Executive Summary
When Novartis announced plans to overhaul its lab space, Scrip's senior science reporter Asher Mullard got to take a look at the company's R&D designs, business strategy and not-for-profit blueprints.